Tumor necrosis factor α is a risk factor for infection in peritoneal dialysis patients

Background/Aims: It has been shown that circulating tumor necrosis factor α (TNF-α) is elevated in end stage renal disease patients; however, the relationship between TNF-α and the development of infection in these patients is unknown. In this study, we investigated the association of plasma TNF-α and interleukin 6 (IL-6) with infection in peritoneal dialysis (PD) patients. We also evaluated the association of their plasma levels with the production by peripheral blood mononuclear cells (PBMC), and with various clinical parameters. Methods: We enrolled 32 patients on maintenance PD and 10 healthy controls. Plasma and PBMC were isolated from blood. PBMC were stimulated with lipopolysaccharide in vitro. Results: Mean follow-up duration was 775 days. Six patients developed organ infections (five pneumonia and one liver abscess), and six patients developed PD peritonitis and eight developed exit site infection. Plasma TNF-α and IL-6 levels were significantly elevated in organ infections but not in peritonitis or in exit site infection. Plasma TNF-α was the only significant risk factor for organ infections and pneumonia in multivariate regression analysis. Patients with high plasma TNF-α levels showed a significantly greater cumulative hazard rate for organ infections compared to those with low TNF-α levels. Plasma TNF-α levels correlated with TNF-α production by PBMC and showed an inverse association with Kt/V. Conclusions: This is the first study showing that plasma TNF-α is a significant risk factor for infection in PD patients.

[1]  R. Shroff,et al.  Malnutrition and its association with inflammation and vascular disease in children on maintenance dialysis , 2013, Pediatric Nephrology.

[2]  A. Cueto-Manzano,et al.  Pentoxifylline decreases serum levels of tumor necrosis factor alpha, interleukin 6 and C-reactive protein in hemodialysis patients: results of a randomized double-blind, controlled clinical trial. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[3]  H. Nonoguchi,et al.  Hepcidin as well as TNF-α are significant predictors of arterial stiffness in patients on maintenance hemodialysis. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[4]  Z. Massy,et al.  Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. , 2010, Kidney international.

[5]  S. Goldstein,et al.  Pro- and anti-inflammatory cytokines in chronic pediatric dialysis patients: effect of aspirin. , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[6]  M. Rocco,et al.  Are nutritional status indicators associated with mortality in the Hemodialysis (HEMO) Study? , 2005, Kidney international.

[7]  C. Zoccali,et al.  Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: searching for the best risk marker by multivariate modeling. , 2005, Journal of the American Society of Nephrology : JASN.

[8]  I. Macdougall,et al.  Pentoxifylline improves hemoglobin levels in patients with erythropoietin-resistant anemia in renal failure. , 2004, Journal of the American Society of Nephrology : JASN.

[9]  S. Mujais,et al.  Impact of Fill Volume on Peritoneal Clearances and Cytokine Appearance in Peritoneal Dialysis , 2004, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[10]  P. Stenvinkel,et al.  Associations between circulating inflammatory markers and residual renal function in CRF patients. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[11]  B. Echtenacher,et al.  Requirement of TNF and TNF receptor type 2 for LPS-induced protection from lethal septic peritonitis , 2002, Journal of endotoxin research.

[12]  P. Stenvinkel,et al.  Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[13]  M. Weisman What are the risks of biologic therapy in rheumatoid arthritis? An update on safety. , 2002, The Journal of rheumatology. Supplement.

[14]  M. Girndt,et al.  Production of proinflammatory and regulatory monokines in hemodialysis patients shown at a single-cell level. , 1998, Journal of the American Society of Nephrology : JASN.

[15]  J. Jenkins,et al.  Bicarbonate/lactate- and bicarbonate-buffered peritoneal dialysis fluids improve ex vivo peritoneal macrophage TNFalpha secretion. , 1998, Journal of the American Society of Nephrology : JASN.

[16]  D. Serur,et al.  Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[17]  R. Selgas,et al.  Anorexigen (TNF-alpha, cholecystokinin) and orexigen (neuropeptide Y) plasma levels in peritoneal dialysis (PD) patients: their relationship with nutritional parameters. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[18]  A. Bakkaloğlu,et al.  Nutritional assessment of children on haemodialysis: value of IGF-I, TNF-alpha and IL-1beta. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[19]  R. Westendorp,et al.  Anti-inflammatory cytokine profile and mortality in febrile patients , 1998, The Lancet.

[20]  B. Jaber,et al.  Effect of glucose concentration, osmolality, and sterilization process of peritoneal dialysis fluids on cytokine production by peripheral blood mononuclear cells and polymorphonuclear cell functions in vitro. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[21]  A. Douvdevani,et al.  Effect of Bicarbonate-Based Dialysis Solutions on Intracellular Ph (Phi) and Tnfα Production by Peritoneal Macrophages , 1997, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[22]  B. Grabensee,et al.  Osmotic agents and buffers in peritoneal dialysis solution: monocyte cytokine release and in vitro cytotoxicity. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[23]  U. Frei,et al.  In vitro biocompatibility evaluation of a novel bicarbonate-buffered amino-acid solution for peritoneal dialysis. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[24]  M. Girndt,et al.  Production of interleukin-6, tumor necrosis factor alpha and interleukin-10 in vitro correlates with the clinical immune defect in chronic hemodialysis patients. , 1995, Kidney international.

[25]  T. Liberek,et al.  Effect of lactate-buffered peritoneal dialysis fluids on human peritoneal mesothelial cell interleukin-6 and prostaglandin synthesis. , 1995, Kidney international.

[26]  D. Gouma,et al.  Influence of nephrectomy on tumor necrosis factor clearance in a murine model. , 1993, Journal of immunology.

[27]  A. Douvdevani,et al.  The effect of peritoneal dialysis fluid on the release of IL-1 beta and TNF alpha by macrophages/monocytes. , 1993, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[28]  G. Pawelec,et al.  IL-4-responsive human helper T cell clones are resistant to growth inhibition by tumor necrosis factor-alpha. , 1989, Journal of immunology.

[29]  A. Nakane,et al.  Endogenous tumor necrosis factor (cachectin) is essential to host resistance against Listeria monocytogenes infection , 1988, Infection and immunity.